Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004
- 1 September 2009
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (9) , 1104-1110
- https://doi.org/10.1097/jto.0b013e3181ae2844
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III studyThe Lancet Oncology, 2008
- Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003Journal of Clinical Oncology, 2008
- Trends in Lung Cancer Incidence by Histological Type in Osaka, JapanJapanese Journal of Clinical Oncology, 2008
- The Role of Osteopontin in Tumor Progression and Metastasis in Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cellsOncogene, 1999
- A Biochemical Characterization of the Binding of Osteopontin to Integrins αvβ1 and αvβ5Journal of Biological Chemistry, 1995
- The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.Journal of Clinical Investigation, 1995